Vance B. Matthews - Search Results

Year	Number of Results
2002	1
2004	2
2005	4
2006	1
2007	2
2008	2
2009	2
2010	1
2011	1
2012	3
2013	2
2015	2
2016	1
2017	4
2018	7
2019	13
2020	13
2021	14
2022	10
2023	3
2024	0

1

Bexagliflozin for type 2 diabetes: an overview of the data.

Azzam O, Carnagarin R, Lugo-Gavidia LM, Nolde J, Matthews VB, Schlaich MP. Azzam O, et al. Among authors: matthews vb. Expert Opin Pharmacother. 2021 Nov;22(16):2095-2103. doi: 10.1080/14656566.2021.1959915. Epub 2021 Jul 29. Expert Opin Pharmacother. 2021. PMID: 34292100 Review.

2

Effects of sympathetic modulation in metabolic disease.

Carnagarin R, Lambert GW, Kiuchi MG, Nolde JM, Matthews VB, Eikelis N, Lambert EA, Schlaich MP. Carnagarin R, et al. Among authors: matthews vb. Ann N Y Acad Sci. 2019 Oct;1454(1):80-89. doi: 10.1111/nyas.14217. Epub 2019 Aug 19. Ann N Y Acad Sci. 2019. PMID: 31424101 Review.

3

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes.

Herat LY, Matthews JR, Hibbs M, Rakoczy EP, Schlaich MP, Matthews VB. Herat LY, et al. iScience. 2023 Jul 3;26(8):107260. doi: 10.1016/j.isci.2023.107260. eCollection 2023 Aug 18. iScience. 2023. PMID: 37520739 Free PMC article.

4

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy.

Herat LY, Matthews JR, Ong WE, Rakoczy EP, Schlaich MP, Matthews VB. Herat LY, et al. Among authors: matthews vb. Front Biosci (Landmark Ed). 2022 Dec 12;27(12):321. doi: 10.31083/j.fbl2712321. Front Biosci (Landmark Ed). 2022. PMID: 36624945 Free article.

5

Multi-organ denervation: a novel approach to combat cardiometabolic disease.

Kiuchi MG, Carnagarin R, Matthews VB, Schlaich MP. Kiuchi MG, et al. Among authors: matthews vb. Hypertens Res. 2023 Jul;46(7):1747-1758. doi: 10.1038/s41440-023-01287-x. Epub 2023 Apr 24. Hypertens Res. 2023. PMID: 37088807 Free PMC article. Review.

6

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.

Herat LY, Matthews J, Azzam O, Schlaich MP, Matthews VB. Herat LY, et al. Among authors: matthews vb. Curr Hypertens Rep. 2022 Mar;24(3):67-74. doi: 10.1007/s11906-022-01170-z. Epub 2022 Mar 2. Curr Hypertens Rep. 2022. PMID: 35235172 Free PMC article. Review.

7

Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.

Azzam O, Matthews VB, Schlaich MP. Azzam O, et al. Among authors: matthews vb. Curr Opin Nephrol Hypertens. 2022 Mar 1;31(2):135-141. doi: 10.1097/MNH.0000000000000767. Curr Opin Nephrol Hypertens. 2022. PMID: 35086983 Review.

8

Liver stem cells.

Matthews VB, Yeoh GC. Matthews VB, et al. IUBMB Life. 2005 Aug;57(8):549-53. doi: 10.1080/15216540500215606. IUBMB Life. 2005. PMID: 16118112 Free article. Review.

9

Overcoming insulin resistance with ciliary neurotrophic factor.

Allen TL, Matthews VB, Febbraio MA. Allen TL, et al. Among authors: matthews vb. Handb Exp Pharmacol. 2011;(203):179-99. doi: 10.1007/978-3-642-17214-4_9. Handb Exp Pharmacol. 2011. PMID: 21484573 Review.

10

New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Azzam O, Kiuchi MG, Ho JK, Matthews VB, Gavidia LML, Nolde JM, Carnagarin R, Schlaich MP. Azzam O, et al. Among authors: matthews vb. Curr Hypertens Rep. 2019 Sep 10;21(10):80. doi: 10.1007/s11906-019-0978-z. Curr Hypertens Rep. 2019. PMID: 31506798 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year